Medpache控股公司在增加预订和提高效率的推动下,由于生物技术和药剂需求不断增长,2025年Q3成果强劲。 Medpace Holdings posted strong Q3 2025 results due to rising biotech and pharma demand, boosted by increased bookings and improved efficiency.

Medpace Holdings 报告称，在生物技术和制药行业需求增长的推动下，其临床研究服务的预订量强劲增长推动了 2025 年第三季度的强劲业绩。 Medpace Holdings reported strong third-quarter 2025 performance fueled by robust booking growth across its clinical research services, driven by rising demand in biotech and pharma sectors. 客户参与增加、服务提供扩大以及技术和效率投资有助于增加收入和改善财政结果,反映出对药物开发解决方案的信心增强。 Increased client engagement, expanded service offerings, and investments in technology and efficiency supported higher revenue and improved financial results, reflecting growing confidence in its drug development solutions.